1. Home
  2. GAUZ vs SKYE Comparison

GAUZ vs SKYE Comparison

Compare GAUZ & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GAUZ
  • SKYE
  • Stock Information
  • Founded
  • GAUZ 2009
  • SKYE 2012
  • Country
  • GAUZ Israel
  • SKYE United States
  • Employees
  • GAUZ N/A
  • SKYE N/A
  • Industry
  • GAUZ Industrial Machinery/Components
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • GAUZ Miscellaneous
  • SKYE Health Care
  • Exchange
  • GAUZ Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • GAUZ 133.9M
  • SKYE 108.3M
  • IPO Year
  • GAUZ 2024
  • SKYE N/A
  • Fundamental
  • Price
  • GAUZ $9.70
  • SKYE $2.70
  • Analyst Decision
  • GAUZ Strong Buy
  • SKYE Buy
  • Analyst Count
  • GAUZ 4
  • SKYE 6
  • Target Price
  • GAUZ $16.25
  • SKYE $18.67
  • AVG Volume (30 Days)
  • GAUZ 93.0K
  • SKYE 193.9K
  • Earning Date
  • GAUZ 02-10-2025
  • SKYE 02-09-2025
  • Dividend Yield
  • GAUZ N/A
  • SKYE N/A
  • EPS Growth
  • GAUZ N/A
  • SKYE N/A
  • EPS
  • GAUZ N/A
  • SKYE N/A
  • Revenue
  • GAUZ $94,346,000.00
  • SKYE N/A
  • Revenue This Year
  • GAUZ $34.69
  • SKYE N/A
  • Revenue Next Year
  • GAUZ $35.73
  • SKYE N/A
  • P/E Ratio
  • GAUZ N/A
  • SKYE N/A
  • Revenue Growth
  • GAUZ 29.76
  • SKYE N/A
  • 52 Week Low
  • GAUZ $6.78
  • SKYE $2.25
  • 52 Week High
  • GAUZ $17.10
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • GAUZ N/A
  • SKYE 25.41
  • Support Level
  • GAUZ N/A
  • SKYE $3.21
  • Resistance Level
  • GAUZ N/A
  • SKYE $3.55
  • Average True Range (ATR)
  • GAUZ 0.00
  • SKYE 0.40
  • MACD
  • GAUZ 0.00
  • SKYE -0.08
  • Stochastic Oscillator
  • GAUZ 0.00
  • SKYE 1.93

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a integrated light and vision control company, Its products include suspended particle device, or SPD, and liquid crystal, or LC, films for smart glass applications, as well as camera monitoring systems, or CMS, and other advanced driver assistance systems, or ADAS, solutions. It has three operating segments. Architecture and automotive segment focuses on sales that enable OEMs to incorporate the Company's technology in glass rooftops, side windows and windshields. Safety tech segment focuses on sales of advanced driver assistance systems for buses, coaches, recreational vehicles and specific vehicles. Aeronautics segment focuses on the sale of shading and cabin management systems in private and commercial aircraft and helicopters. Key revenue is generated from Aeronauctis.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: